Regeneron Pharmaceuticals Inc. Stock
Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Regeneron Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.090% | -2.076% | -4.969% | 13.999% | 5.279% | 100.119% | 181.367% |
| Exact Sciences | 1.130% | -12.960% | 10.118% | 0.000% | -12.972% | -45.058% | -29.420% |
| Incyte Corp. | -0.300% | -3.086% | -6.023% | -26.249% | -12.548% | -28.066% | -24.186% |
| Amgen Inc. | -0.240% | -1.927% | -0.943% | 10.004% | -5.276% | 15.648% | 56.234% |
Comments
News
Should You Sell This Stock Following a Regulatory Roadblock?
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its
2 Biotech Stocks to Buy Hand Over Fist in March
Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry
2 No-Brainer Biotech Stocks to Buy Right Now
Those looking to invest in stocks can sometimes seem spoiled for choices. There are all kinds of businesses in the equity markets that seem intriguing. However, upon closer inspection, many of these